Holland Pouncey, PA
Physician Assistant · Luverne, ALNPI 1447617147
Payments from drug & device makers
Across 288 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$707
- Novo Nordisk$652
- AstraZeneca$641
- Otsuka America Pharmaceutical, Inc.$424
- GSK$353
- Bayer$209
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,12398%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $707 |
| Novo Nordisk | 41 | $652 |
| AstraZeneca | 34 | $641 |
| Otsuka America Pharmaceutical, Inc. | 19 | $424 |
| GSK | 20 | $353 |
| Bayer | 10 | $209 |
| Lilly USA, LLC | 14 | $209 |
| Pfizer | 11 | $196 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $177 |
| Merck | 11 | $162 |
| Axsome Therapeutics, Inc. | 5 | $145 |
| Neurocrine Biosciences, Inc. | 6 | $119 |
| Boehringer Ingelheim | 7 | $118 |
| Astellas Pharma US Inc | 2 | $116 |
| Phathom Pharmaceuticals, Inc. | 7 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| Radius Health, Inc. | 3 | $88 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Ardelyx, Inc. | 4 | $66 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Abbott | 2 | $45 |
| Lundbeck LLC | 2 | $43 |
| Dexcom, Inc. | 2 | $43 |
| Johnson & Johnson | 2 | $36 |
| Medtronic | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Exact Sciences | 2 | $29 |
| Amgen | 2 | $26 |
| Novartis | 1 | $20 |
| Corcept Therapeutics | 1 | $17 |
| Mylan Specialty L.p. | 1 | $13 |
| Genentech USA, Inc. | 1 | $7 |
How this compares
$5,222 in reported general payments places this provider in the 90th percentile of 846 physician assistant providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 275 | $195,233 |
| OzempicSemaglutide | 152 | $153,674 |
| FarxigaDapagliflozin Propanediol | 195 | $145,000 |
| JardianceEmpagliflozin | 131 | $114,290 |
| MounjaroTirzepatide | 96 | $102,677 |
| TrulicityDulaglutide | 84 | $91,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $86,771 |
| LinzessLinaclotide | 79 | $45,821 |
| XareltoRivaroxaban | 49 | $42,061 |
| RybelsusSemaglutide | 41 | $38,623 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $38,287 |
| EntrestoSacubitril/Valsartan | 45 | $36,194 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $20,306 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $19,953 |
| Repatha SureclickEvolocumab | 28 | $14,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $196 | $195,233275 claims |
| Lilly USA, LLCMounjaro, Trulicity | $209 | $193,801180 claims |
| Novo NordiskOzempic, Rybelsus | $652 | $192,297193 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $641 | $183,288254 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $118 | $123,223150 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $353 | $102,990152 claims |
| AbbVieLinzess | $707 | $45,82179 claims |
| Johnson & JohnsonXarelto | $36 | $42,06149 claims |
| NovartisEntresto | $20 | $36,19445 claims |
| Astellas Pharma US IncMyrbetriq | $116 | $12,89027 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $185 | $6,96913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 physician assistant providers in Alabama.
Other physician assistant in Luverne
- Natalie GeorgeBirmingham$540K
- Lauren MillerAnniston$487K
- Valerie GoodwinBirmingham$33K
- Brianna BarryEnterprise$29K
- Ashley PeaceMobile$27K
- Andrea WombleHuntsville$22K
- Marlee BrunoDecatur$19K
- Mary TemplinBirmingham$19K
- Gregory SharpMobile$19K
- Elizabeth SimpsonMobile$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.